BeOne Medicines Ltd
144 hedge funds and large institutions have $7.84B invested in BeOne Medicines Ltd in 2018 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 53 increasing their positions, 37 reducing their positions, and 20 closing their positions.
85% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 20
43% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 37
21% more capital invested
Capital invested by funds: $6.48B → $7.84B (+$1.36B)
13% more funds holding
Funds holding: 128 → 144 (+16)
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
0.09% less ownership
Funds ownership: 6.04% → 5.95% (-0.09%)
63% less call options, than puts
Call options by funds: $11.4M | Put options by funds: $31M
Top Buyers
Top Sellers
ONC Hedge Fund Activity: Q3 2018 in Review
144 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q3 2018, worth a combined $7.84B — up 21% from $6.48B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new ONC positions and 20 closed out — a net gain of 17 holders — while 53 added to existing stakes and 37 trimmed.
The largest buyer was HSBC Holdings, adding an estimated $408M. The largest seller was Capital World Investors, exiting entirely with an estimated $281M sold.
- 144 institutional investors held BeOne Medicines Ltd (ONC) as of Q3 2018, up from 128 in Q2 2018.
- Funds reported $7.84B of BeOne Medicines Ltd stock for Q3 2018, up 21% quarter-over-quarter.
- 37 funds opened new BeOne Medicines Ltd positions in Q3 2018 and 20 closed out, a net change of +17 holders.
- The largest BeOne Medicines Ltd buyer in Q3 2018 was HSBC Holdings, an estimated $408M added.
- The largest BeOne Medicines Ltd seller in Q3 2018 was Capital World Investors, an estimated $281M sold.
Based on aggregated 13F filings for Q3 2018.